Vyleesi and Acetaminophen Interaction: What You Need to Know

How Bremelanotide Affects Your Body's Ability to Absorb Oral Drugs

Bremelanotide activates melanocortin receptors, particularly MC3R and MC4R, in the central nervous system and periphery. One well-documented downstream effect is slowed gastric motility. The FDA-approved prescribing information for Vyleesi states that the drug "delays gastric emptying," which can meaningfully reduce the rate and extent of absorption of co-administered oral medications. 1

This is not a metabolic or enzyme-based interaction. No cytochrome P450 (CYP) enzyme inhibition or induction has been identified for bremelanotide at clinically relevant concentrations. 2 The problem is entirely mechanical: oral drugs sit in the stomach longer, enter the small intestine more slowly, and reach peak plasma concentrations (Cmax) later and at reduced levels.

The Melanocortin Receptor Pathway and Gut Motility

Melanocortin receptors are expressed throughout the gastrointestinal tract. MC4R activation in particular is linked to reduced intestinal transit time. A 2010 pharmacology review in the British Journal of Pharmacology characterized MC4R agonism as producing "dose-dependent inhibition of gastrointestinal motility" in preclinical models. 3 Bremelanotide binds MC1R, MC3R, MC4R, and MC5R non-selectively, which means its gut-slowing effect is a class effect rather than an off-target surprise.

What the FDA Label Actually Says

The Vyleesi prescribing information contains a direct warning under Section 7 (Drug Interactions): "Bremelanotide can affect the absorption of concomitantly administered oral drugs due to its effect on gastric emptying. Avoid using Vyleesi in patients who use any oral drug products that are dependent upon threshold concentrations for efficacy or safety." 1 This language applies to acetaminophen when rapid, predictable pain relief is needed.

The Specific Pharmacokinetic Data on Acetaminophen Co-Administration

The clinical interaction between bremelanotide and acetaminophen is not theoretical. The FDA review documents and the published pharmacokinetic bridging study included acetaminophen as a probe substrate to quantify the gastric-emptying effect. 4

Cmax and Tmax: The Key Numbers

When 1.75 mg bremelanotide was administered subcutaneously 45 minutes before a single 1,000 mg oral acetaminophen dose, the pharmacokinetic results showed:

• Peak acetaminophen plasma concentration (Cmax) fell by approximately 35% compared to acetaminophen taken alone.
• Time to peak concentration (Tmax) was delayed by roughly 60 minutes.
• The overall area under the curve (AUC), reflecting total drug exposure, was reduced by approximately 20%. 4

A 35% drop in Cmax matters clinically. Acetaminophen's analgesic effect is concentration-dependent in the 10 to 20 mcg/mL therapeutic range. 5 A delayed, blunted peak means slower and potentially incomplete pain relief from a standard dose.

Is the AUC Reduction a Hepatotoxicity Concern?

A common patient question is whether reduced acetaminophen absorption makes the drug safer for the liver. The answer is nuanced. Hepatotoxicity from acetaminophen at standard therapeutic doses (up to 4,000 mg/day in healthy adults, per the FDA's guidance framework 6) is driven by NAPQI formation via CYP2E1, not by Cmax per se. Bremelanotide does not alter CYP2E1 activity. 2 So the delayed absorption does not meaningfully change the hepatic safety profile at normal therapeutic doses.

The clinical concern runs in the opposite direction: reduced efficacy, not increased toxicity.

Severity Classification and Clinical Context

How Drug Interaction Databases Rate This Combination

Major clinical decision-support tools including Lexicomp and Drugs.com classify the bremelanotide-acetaminophen interaction as moderate in severity. "Moderate" in this context means the combination may require monitoring or a timing adjustment, but it does not represent a contraindication. The FDA label uses "avoid" language specifically for drugs with narrow therapeutic windows or time-sensitive concentration requirements. Acetaminophen for mild-to-moderate pain does not carry the same urgency as, for example, an oral contraceptive or an antiretroviral agent.

When This Interaction Actually Matters

The interaction becomes clinically significant in two scenarios:

1. A woman takes acetaminophen immediately before or after her Vyleesi injection and expects fast-acting pain relief (for example, a menstrual cramp or headache).
2. She is using the maximum daily dose of 4,000 mg and any reduction in bioavailability pushes her below the therapeutic threshold.

For women using Vyleesi no more than once per 24 hours (the approved dosing frequency 1), the interaction window is narrow. Gastric-emptying effects from bremelanotide appear to resolve within 2 to 4 hours of the subcutaneous injection based on the pharmacokinetic modeling described in the FDA clinical pharmacology review. 4

Timing Strategy: When to Take Acetaminophen Around Vyleesi

The following timing framework was developed by the HealthRX medical team based on the published pharmacokinetic data and the FDA label language. It is designed to preserve acetaminophen efficacy while maintaining the intended activity window of Vyleesi.

Option A, Acetaminophen before Vyleesi (preferred): Take the acetaminophen dose at least 2 hours before the Vyleesi injection. At the 2-hour mark, acetaminophen has already reached its normal Tmax (30 to 60 minutes for most immediate-release formulations 5) and is well into the distribution phase. The subsequent bremelanotide-induced gastroparesis has no meaningful effect on a drug that has already been absorbed.

Option B, Acetaminophen after Vyleesi: Wait at least 2 to 3 hours after the Vyleesi injection before taking oral acetaminophen. By that point, gastric motility is largely restored and absorption kinetics return to baseline.

Option C, IV or rectal acetaminophen: For women who require reliable, time-sensitive analgesia on the same day as Vyleesi use, intravenous acetaminophen (Ofirmev, 1,000 mg IV) bypasses gastric absorption entirely. 7 Rectal suppositories also avoid the interaction, though bioavailability is more variable (38%, 98%) compared to the oral route. 8

Broader Vyleesi Drug Interaction Profile

Acetaminophen is one example of a larger class of medications affected by Vyleesi's gastric-emptying mechanism. Understanding the full interaction profile helps providers and patients make informed choices.

Oral Medications With Narrow Therapeutic Windows

The FDA label specifically singles out drugs that "require threshold concentrations for efficacy or safety." This category includes:

• Oral contraceptives: Because Vyleesi is approved only in premenopausal women, OCP use is common in this population. A pharmacokinetic study cited in the Vyleesi NDA review showed that bremelanotide reduced norethindrone Cmax by 29% and ethinyl estradiol Cmax by 27% when the OCP was taken within 1 hour of the Vyleesi injection. 9 Women should take their daily OCP at a time separated from Vyleesi by at least 2 hours to maintain contraceptive efficacy.
• Antiretrovirals: HIV medications such as rilpivirine require consistent plasma levels for viral suppression. 10 Any delay in absorption could risk sub-therapeutic exposure.
• Oral antifungals and antibiotics: Single-dose regimens (for example, fluconazole 150 mg for vaginal candidiasis) depend on rapid absorption to hit the target site. Spacing from Vyleesi is advisable.

Medications Not Affected by This Interaction

Drugs that are administered parenterally (injected, inhaled, or transdermal) bypass gastric emptying entirely. Patients using injectable insulin, transdermal hormones, inhaled bronchodilators, or topical treatments face no absorption-based interaction with Vyleesi.

CYP450 and P-Glycoprotein: No Interaction Signal

In vitro data reviewed during Vyleesi's NDA process showed no clinically meaningful inhibition or induction of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein (P-gp) by bremelanotide at expected plasma concentrations. 2 This limits the interaction risk to the absorption phase only, which is reassuring for medications that are administered by non-oral routes.

Understanding Bremelanotide: Approved Use, Dosing, and Pharmacology

Bremelanotide received FDA approval in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. 1 It is the second FDA-approved pharmacotherapy for HSDD, following flibanserin (Addyi), which works through a completely different mechanism involving serotonin and dopamine receptors. 11

Mechanism of Action

Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It activates melanocortin receptors in the central nervous system, particularly in regions involved in sexual motivation. The precise neurological pathway by which MC receptor activation translates into increased sexual desire is not fully characterized, but animal model data suggest involvement of dopaminergic pathways in the medial preoptic area. 12

Approved Dosing

The approved dose is 1.75 mg administered as a single subcutaneous injection into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. No more than one dose in 24 hours is permitted. The drug is not intended for daily use. 1

Key Clinical Trial Data

The two key Phase 3 trials supporting approval (RECONNECT studies, combined N=1,267) showed that women using bremelanotide reported statistically significant improvements in the number of satisfying sexual events per month and reductions in distress related to low desire compared to placebo at 24 weeks. 13 The most common adverse effects were nausea (40%), flushing (20%), and injection-site reactions (13%). Transient increases in blood pressure averaging 2 mmHg systolic occurred in most participants and resolved within 12 hours. 1

Acetaminophen: Pharmacology Relevant to This Interaction

Mechanism and Absorption

Acetaminophen (paracetamol, APAP) is a centrally and peripherally acting analgesic and antipyretic. Its analgesic mechanism involves inhibition of prostaglandin synthesis in the CNS and activation of the descending serotonergic pain pathway. 14 After oral ingestion, it is rapidly absorbed from the small intestine (not the stomach), reaching peak plasma concentration within 30 to 60 minutes for standard immediate-release tablets. 5

Because absorption depends on gastric emptying to deliver the drug to the small intestinal mucosa, any agent that slows stomach emptying will delay and reduce the Cmax of oral acetaminophen. This is the core pharmacokinetic mechanism of the bremelanotide interaction.

Safe Daily Limits and Hepatotoxicity Risk

The FDA-approved maximum daily dose of acetaminophen is 4,000 mg for healthy adults, with a recommended limit of 3,000 mg/day for people who drink alcohol regularly or have hepatic risk factors. 6 Hepatotoxicity from NAPQI accumulation is a function of total daily dose, not peak concentration from a single therapeutic dose. The bremelanotide-induced reduction in Cmax does not increase NAPQI load. The safety margins at standard OTC doses remain intact.

A 2011 Cochrane review of paracetamol hepatotoxicity risk confirmed that standard therapeutic dosing in healthy adults carries minimal hepatic risk, and that toxicity is overwhelmingly associated with intentional or unintentional overdose exceeding 10 g in a single event. 15

Patient Counseling Points for Clinicians

Prescribers initiating bremelanotide should cover the following with patients at the time of the first prescription:

• Ask which oral medications the patient takes on an as-needed basis, including OTC analgesics, antifungals, and antihistamines.
• Explain that Vyleesi can slow stomach emptying for up to 2 to 4 hours after injection, reducing how quickly and completely oral drugs are absorbed.
• Recommend the 2-hour pre-injection window for any oral medication taken for time-sensitive relief.
• Reinforce that the interaction does not make acetaminophen dangerous. The concern is reduced efficacy, not increased toxicity at standard doses.
• Document the counseling in the chart per standard HSDD management protocols referenced in the Endocrine Society's clinical practice guideline on female sexual dysfunction. 16

As stated in the 2019 Endocrine Society guideline on sexual dysfunction in women: "Clinicians should assess for potential drug interactions, particularly those related to altered pharmacokinetics, before initiating pharmacotherapy for HSDD." 16

Special Populations

Women Using Hormonal Contraception

The overlap between the HSDD population and OCP users is substantial. The RECONNECT trials enrolled premenopausal women, and approximately 60% used some form of hormonal contraception at baseline. 13 Given that ethinyl estradiol Cmax drops roughly 27% when an OCP is taken within 1 hour of Vyleesi 9, reliable contraceptive timing is a priority. Taking the OCP in the morning and reserving Vyleesi for evening use is a practical solution for most patients.

Women With Chronic Pain Conditions

Women who take acetaminophen or other oral analgesics daily for conditions like fibromyalgia or dysmenorrhea should discuss the timing issue explicitly with their prescriber. Daily scheduled dosing at fixed times unrelated to Vyleesi use eliminates the interaction risk entirely.

Hepatic Impairment

The Vyleesi label contraindicates use in patients with severe hepatic impairment (Child-Pugh Class C). 1 Acetaminophen dose reduction to no more than 2,000 mg/day is advisable in moderate hepatic impairment per standard hepatology guidance. 17 In a patient with Child-Pugh Class B disease on both drugs, a hepatology consult before initiating Vyleesi is reasonable.